Cargando…
Expression of CD 133 in Invasive Ductal Carcinoma of Breast
BACKGROUND: CD133 is a commonly used cancer stem cell (CSC) marker in breast cancer. However, the association between CD133 expression, with clinicopathological features and prognosis in breast cancer, is poorly understood in the Indian subcontinent. This study was designed to explore the expression...
Autores principales: | Utnal, Preeti Ashok, A, Hemalatha, PN, Sreeramulu, GN, Manjunath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798163/ https://www.ncbi.nlm.nih.gov/pubmed/33112567 http://dx.doi.org/10.31557/APJCP.2020.21.10.3055 |
Ejemplares similares
-
Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis
por: Han, Zhengquan, et al.
Publicado: (2015) -
Association between ALDH1+/CD133+ stem-like cells and tumor angiogenesis in invasive ductal breast carcinoma
por: LV, XINQUAN, et al.
Publicado: (2016) -
Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas
por: Immervoll, Heike, et al.
Publicado: (2008) -
CD31 expression by cells of extensive ductal in situ and invasive carcinomas of the breast
por: Sapino, A, et al.
Publicado: (2001) -
In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
por: Brugnoli, Federica, et al.
Publicado: (2013)